The development of environmentally favourable, cost-effective techniques to treat azo dyes in textile wastewater have attracted a great attention.
In this article, we will combine the most up-to-date and clinically relevant efficacy data, the most recent cost data and the latest epidemiology data from a large Italian ICU database to determine whether i.v. glutamine supplementation remains a highly favourable cost-effective option in total PN therapy for intensive care patients.
Behavioural risk factors can vary over time, so a combination of multiple interventions addressing the full range of risk factors for chronic disease and morbidity, could generate larger health gains than a single intervention, often with a favourable cost-effective profile.
If similar levels of protection could be achieved with removal of the infant meningococcal group C conjugate vaccine or by using a 2, 4, and 12 months schedule this would be more economically favourable and could be cost effective at a cost of £6-7 a dose, or up to £22 a dose if several further vaccine favourable assumptions were combined.
This study is a pharmacoeconomic analysis to determine whether i.v. glutamine supplementation of PN remains both a highly favourable and cost-effective option for Italian ICU patients.
Our results suggest that routine infant vaccination could be cost effective in England under favourable assumptions if the vaccine could be procured at <20% of the list price.
Thus, dietary intervention plus quadriceps strengthening exercises is likely to be deemed cost effective as it has an incremental cost effectiveness ratio that is more favourable than a threshold of £20 000-£30 000 per QALY.
If the true estimate is lower, any bias introduced from this assumption would have favoured the cost-effectiveness of U-IUI, and would have made IVF less cost effective, i.e. if a lower LBR value for U-IUI was used, the results would have been even more favourable for primary offer of IVF as the preferred treatment strategy.
Thus, development of a novel cost effective media to support yeast growth will be favourable for many applications in industrial scale.
This strategy could be cost effective at £3 (€3.8, $4.9) a vaccine dose, given several favourable assumptions and the use of a quality of life adjustment factor.
There are, however, some favourable attributes associated with ACTG use in comparison to PSG in that it is cost effective, is easy to interpret and is able to collect data over an extended period.
